EARS tinnitus post-mortem: EARS never established PoC for Keyzilen (f/k/a AM-101) in phase-2; rather, they used post-hoc subset analysis to justify advancing Keyzilen to phase-3.
The second Keyzilen phase-3 trial (TACTT3) has a slightly different design from TACTT2 and is due to report results in a few months, but it’s very unlikely to succeed, IMO.
Market Data 
Markets 
AI
